New trends in cancer for the 21st century

406 Pages·2006·8.548 MB·English

by  P. Picci, K. Scotlandi, M. Serra, A. Rizzi (auth.), Antonio Llombart-Bosch, Vicente Felipo, José Antonio López-Guerrero (eds.)

López-Guerrero,
ADVANCES IN
Llombart-Bosch
EXPERIMENTAL
Felipo
MEDICINE
N
E
AND BIOLOGY
W

T
R Volume 587
E
N
D
S

I
N

C
A
NEW TRENDS IN
N
C
E
R

F CANCER FOR THE
O
R

T
H
E 21ST CENTURY

2
1
S
T

C
E
N
T
U
R
Y
AEMB
Edited by
587
J.A. López-Guerrero,
A. Llombart-Bosch
and V. Felipo
NEW TRENDS IN CANCER FOR THE
21st CENTURY
2nd Edition
ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY
Editorial Board:
NATHAN BACK,State University ofNew York at Buffalo
IRUN R.COHEN,The Weizmann Institute ofScience
DAVID KRITCHEVSKY,Wistar Institute
ABEL LAJTHA,N.S.Kline Institute for Psychiatric Research
RODOLFO PAOLETTI,University ofMilan
Recent Volumes in this Series
Volume 579
IMMUNE MECHANISMS IN INFLAMMATORY BOWEL DISEASE
Edited by Richard S.Blumberg
Volume 580
THE ARTERIAL CHEMORECEPTORS
Edited by Yoshiaki Hayashida,Constancio Gonzalez,and Hisatake Condo
Volume 581
THE NIDOVIRUSES:THE CONTROL OF SARS AND OTHER
NIDOVIRUS DISEASES
Edited by Stanley Perlman and Kathryn Holmes
Volume 582
HOT TOPICS IN INFECTION AND IMMUNITY IN CHILDREN III
Edited by Andrew J.Pollard and Adam Finn
Volume 583
TAURINE 6
Edited by Simo S.Oja and Pirjo Saransaari
Volume 584
LYMPHOCYTE SIGNAL TRANSDUCTION
Edited by Constantine Tsoukas
Volume 585
TISSUE ENGINEERING
Edited by John P.Fisher
Volume 586
CURRENT TOPICS IN COMPLEMENT
Edited by John D.Lambris
Volume 587
NEW TRENDS IN CANCER FOR THE 21STCENTURY
Edited by J.A.López-Guerrero,A.Llombart-Bosch and V.Felipo
A Continuation Order Plan is available for this series.A continuation order will bring delivery of
each new volume immediately upon publication.Volumes are billed only upon actual shipment.For
further information please contact the publisher.
NEW TRENDS IN
CANCER FOR THE
21st CENTURY
2nd Edition
Edited by
Antonio Llombart-Bosch
University of Valencia,
Valencia,Spain
Vicente Felipo
Centro de Investigación Prínicpe Felipe,
Valencia,Spain
and
José Antonio López-Guerrero
Fundación Instituto Valenciano de Oncología,
Valencia,Spain
ISBN-10 1-4020-4966-8 (HB)
ISBN-13 978-1-4020-4966-8 (HB)
ISBN-10 1-4020-5133-6 (e-book)
ISBN-13 978-1-4020-5133-3 (e-book)
© 2006 Springer
All rights reserved. This work may not be translated or copied in whole or in part without the
written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street,
New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly
analysis. Use in connection with any form of information storage and retrieval, electronic
adaptation,computer software,or by similar or dissimilar methodology now known or hereafter
developed is forbidden.
The use in this publication oftrade names,trademarks,service marks,and similar terms,even ifthey
are not identified as such, is not to be taken as an expression of opinion as to whether or not
they are subject to proprietary rights.
9 8 7 6 5 4 3 2 1
springer.com
Honoring the memory of Prof.Antonio Llombart Rodríguez.
Commemorating the centenary of his birth and the 50th anniversary
of thefounding of the Spanish Association
Against Cancer (AECC) inValencia
Contents
Preface.............................................................................................................xi
List of Contributors.......................................................................................xvii
1. Prognostic and Therapeutic Targets in the Ewing’s Family
of Tumors (PROTHETS)...........................................................................1
P.Picci,K.Scotlandi,M.Serra,and A.Rizzi
2. Targeted Therapies in Ewing’s Sarcoma...................................................13
K.Scotlandi
3. The CCN3 Protein and Cancer................................................................23
B.Perbal
4. Ews-Fli1 in Ewing’s Sarcoma:Real Targets
and Collateral Damage.............................................................................41
J.Ban,C.Siligan,M.Kreppel,D.Aryee,and H.Kovar
5. Molecular Karyotyping in Sarcoma Diagnostics and Research................53
H.Vauhkonen,S.Savola,S.Kaur,M.L.Larramendy,
and S.Knuutila
6. TuBaFrost:European Virtual Tumor Tissue Banking..............................65
P.H.J.Riegman,M.H.A.Oomen,W.N.M.Dinjens,J.W.Oosterhuis,
K.H.Lam,A.Spatz,C.Ratcliffe,K.Knox,R.Mager,
vii
viii CONTENTS
D.Kerr,F.Pezzella,B.van Damme,M.van de Vijver,
H.van Boven,M.M.Morente,S.Alonso,D.Kerjaschki,
J.Pammer,J.A.López-Guerrero,A.Llombart-Bosch,
A.Carbone,A.Gloghini,I.Teodorovic,M.Isabelle,
A.Passioukov,S.Lejeune,P.Therasse,andE.-B.van Veen
7. Virtual Microscopy in Virtual Tumor Banking.........................................75
M.Isabelle,I.Teodorovic,J.W.Oosterhuis,P.H.J.Riegman,
and the TuBaFrost Consortium
8. Harmonizing Cancer Control in Europe..................................................87
U.Ringborg
9. The Diagnosis of Cancer:“From H&E to Molecular
Diagnosis and Back”................................................................................95
J.Costa
10. From Morphological to Molecular Diagnosis of Soft Tissue Tumors......99
M.Miettinen
11. Prediction of Response to Neoadjuvant Chemotherapy
in Carcinomas of the Upper Gastrointestinal Tract...............................115
H.Höfler,R.Langer,K.Ott,and G.Keller
12. Integrating the Diagnosis of Childhood Malignancies...........................121
D.López-Terrada
13. Preclinical Models for Cell Cycle-Targeted Therapies.............................139
M.Malumbres
CONTENTS ix
14. WWOX,a Chromosomal Fragile Site Gene and its Role in Cancer.......149
D.Ramos,and C.M.Aldaz
15. From Genome to Proteome in Tumor Profiling:Molecular
Events in Colorectal Cancer Genesis......................................................161
J.K.Habermann,U.J.Roblick,M.Upender,T.Ried,
and G.Auer
16. Effect of Hypoxia on the Tumor Phenotype:The Neuroblastoma
and Breast Cancer Models......................................................................179
L.Holmquist,T.Löfstedt,and S.Påhlman
17. Methylation Patterns and Chemosensitivity in NSCLC..........................195
J.L.Ramírez,M.F.Salazar,J.Gupta,J.M.Sánchez,M.Taron,
M.Sánchez-Ronco,Vicente Alberola,and R.de las Peñas
18. Pharmacogenomics and Colorectal Cancer............................................211
H.J.Lenz
19. Development of Pharmacogenomic Predictors for Preoperative
Chemotherapy of Breast Cancer............................................................233
L.Pusztai
20. Vascular Endothelial Growth Factor Inhibitors
in Colon Cancer.....................................................................................251
E.Díaz-Rubio
21. Molecular Imaging of Cancer Using PET and SPECT..........................277
A.Kjær
x CONTENTS
22. MRS as Endogenous Molecular Imaging for Brain
and Prostate Tumors:FP6 Project “eTUMOR”.....................................285
B.Celda,D.Monleón,M.C.Martínez-Bisbal,V.Esteve,
B.Martínez-Granados,E.Piñero,R.Ferrer,J.Piquer,
L.Martí-Bonmatí,and J.Cervera
23. From Linac to Tomotherapy:New Possibilities for Cure?......................303
G.Storme,D.Verellen,G.Soete,N.Linthout,J.Van de Steene,
M.Voordeckers,V.Vinh-Hung,K.Tournel,and D.Van den Berge
24. Targeting mTOR for Cancer Treatment..................................................309
B.Rubio-Viqueira,and M.Hidalgo
25. Dual/Pan-Her Tyrosine Kinase Inhibitors:Focus
in Breast Cancer.....................................................................................329
J.Albanell
26. AntiTumor-Associated Antigens IGGS:Dual Positive
and Negative Potential Effects for Cancer Therapy................................341
E.Barberá Guillem,and J.W.Sampsel
27. Synergistic Molecular Mechanisms in Hormone-Sensitive
Breast Cancer.........................................................................................375
A.Llombart Cussac
Index.............................................................................................................387